An In-Depth Analysis of MC-1-50: A CD19-Targeted CAR-T Cell Therapy from Chongqing Precision Biotechnology

Executive Summary

An investigation into the designation "MC150" reveals a significant nomenclature ambiguity, with the term referring to multiple disparate entities across pharmaceutical, legal, and industrial domains. However, the most clinically and scientifically significant subject is the investigational cell therapy MC-1-50, an autologous Chimeric Antigen Receptor T-cell (CAR-T) therapy developed by Chongqing Precision Biotechnology Co., Ltd. This report focuses exclusively on this therapeutic candidate.

MC-1-50 is a CD19-targeting immunotherapy distinguished by its innovative PrimeCAR™ manufacturing platform. This proprietary process enables the rapid production of CAR-T cells in approximately two to three days, a substantial improvement over conventional methods. Crucially, the platform enriches the final product for stem cell-like memory T (Tscm​) cells, a potent T-cell subset associated with enhanced persistence and anti-tumor activity.

This advanced manufacturing process translates into a highly favorable clinical profile. In early-phase trials for relapsed/refractory (r/r) B-cell malignancies, MC-1-50 has demonstrated remarkable efficacy, including 100% complete response rates in both B-cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia (B-ALL) at very low cell doses. This high efficacy is coupled with an exceptionally mild safety profile. Rates of severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)—the two most significant toxicities associated with CAR-T therapy—are notably low, with no dose-limiting toxicities reported.